Subscribe

Palonosetron Receives New Indication for CINV Prevention in Pediatric Patients

VBCC - June 2014 Vol 5, No 5 - FDA Approvals, News & Updates

Palonosetron HCl (Aloxi; Eisai) injection received a new US Food and Drug Administration (FDA) indication for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) associated with initial or repeated courses of emetogenic chemotherapy in children aged 1 month to <17 years. This is the first FDA approval of a therapy for the prevention of acute CINV in patients aged 1 month to 6 months. The age of peak cancer incidence among children occurs within the first year of life, so this approval provides an important option to children, and especially infants, undergoing chemotherapy.

The FDA approval was based on 1 randomized, double-blind, noninferiority pivotal trial comparing palonosetron with ondansetron in pediatric patients. The primary end point was complete response, which was achieved in 59.4% of patients using palonosetron compared with 58.6% of patients receiving ondansetron.

The trial also showed that pediatric patients required a higher dose of palonosetron based on weight than that required by adults; however, the safety profile of the drug in pediatric patients was consistent with its safety profile in adults.

Palonosetron HCl is already approved for the prevention of CINV in adults aged ≥17 years. (May 28, 2014)

Related Items
FDA News - December 2017
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in FDA Approvals, News & Updates
FDA News - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in FDA Approvals, News & Updates
Scott Gottlieb, MD, Appointed as New FDA Commissioner
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA Approvals, News & Updates
New Drugs Approved for Giant-Cell Arteritis and Moderate-to-Severe Rheumatoid Arthritis
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA Approvals, News & Updates
FDA Releases Draft Guidances on Sharing Healthcare Economic Information, Industry Communication Regulations
Leslie Wyatt
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in FDA Approvals, News & Updates
FDA News - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in FDA Approvals, News & Updates
FDA Approves First Tissue-Engineered Autologous Cellularized Scaffold Product for the Repair of Cartilage Defects
Web Exclusives published on December 15, 2016 in FDA Approvals, News & Updates, In the News
FDA News - November 2016
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in FDA Approvals, News & Updates
Abuse-Deterrent Oxycodone Extended-Release Capsules Approved for Chronic Pain
Web Exclusives published on November 7, 2016 in FDA Approvals, News & Updates, In the News
FDA News - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in FDA Approvals, News & Updates
Last modified: July 1, 2014
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology